Can you get medical cannabis for autism in the UK?

Autism is not an illness and there is no medicine for it. What is sometimes assessed is a specific associated problem — severe irritability, aggression or self-injury — where other treatments have failed. Keeping those two ideas apart is the whole of this page.

The short answer

  • Autism itself is not a treatment target. No medicine treats autism.
  • What is assessed is severe associated behaviour that has not responded to other approaches.
  • One placebo-controlled trial exists, in children and adolescents, with mixed results.
  • Most UK private prescribing is for adults. Prescribing for children is a different and far more restricted matter.
  • Behavioural and environmental support comes first, and is what NICE recommends.

Is autism treated with medical cannabis in the UK?

Autism is a developmental difference, not a disease with a target for drug treatment, and no cannabis-based product is licensed for it anywhere in the UK. What a specialist may occasionally assess is a specific, severe, associated symptom — most often irritability, aggression or self-injurious behaviour — in someone for whom the recommended approaches have not worked.

NICE guidance on autism centres on psychosocial and environmental support, with medication reserved for coexisting conditions such as anxiety, ADHD, epilepsy or sleep problems, or for severe behaviour that puts someone at risk. That framing matters: if the real problem is anxiety or insomnia, the honest conversation is about that condition, not about autism.

It is also worth saying plainly that a good deal of online material presents cannabis as a treatment for autism itself. That claim is not supported, and it is not one a careful UK specialist will make.

What the evidence actually shows

There is one properly controlled trial and a larger body of open-label observational reports. The controlled trial produced a more modest picture than the observational data, which is the usual pattern in this field.

The trial randomised 150 children and adolescents with autism and moderate to severe behaviour problems to a whole-plant cannabis extract, a purified cannabidiol and THC mixture, or placebo, in a crossover design. Improvement in disruptive behaviour was reported on some measures with the whole-plant extract, but the results were not consistent across outcomes and the effect on the core features of autism was not established.

The study behind that paragraph

Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism. 2021;12(1):6. A placebo-controlled crossover trial in 150 children and adolescents. The authors described the findings as preliminary and called for larger trials.

Read the paper →

A broad systematic review of cannabinoids in mental health found the evidence across psychiatric and neurodevelopmental indications insufficient to support routine use. UK registry data reports improvements in quality-of-life measures for people prescribed in relation to autism, and carries the same observational limits as the rest of that dataset.

What a specialist will want to see

There is no UK list of qualifying conditions. For autism the assessment turns almost entirely on what specific problem is being treated, and on what has already been tried for it.

Where the patient is under 18, this stops being a routine private matter. Prescribing cannabis-based medicines to children in the UK is restricted, is normally led by a paediatric specialist within the NHS, and is not something a general private teleclinic route covers. Flora House is an adult service.

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

The developing brain is the central concern. THC exposure in adolescence is associated with poorer cognitive and mental health outcomes, which is why the threshold for anyone under 25 is higher, and much higher again under 18.

Communication difficulties add a second, practical risk: side effects are harder to detect and report in someone who does not readily describe how they feel. A careful specialist will want a clear plan for who is monitoring, what they are watching for, and when treatment stops if it is not helping.

A personal or family history of psychosis, unstable mental illness, pregnancy or breastfeeding will normally count against treatment, as they do throughout this field.

If you want to take this further

The useful next step is a proper assessment, not a longer reading list. Gather your diagnosis, the treatments you have already tried and what happened with each, and a current list of your medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If autism is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Frequently asked questions

Can medical cannabis treat autism?

No. Autism is a developmental difference, not a condition any medicine treats. What is occasionally assessed is a severe associated symptom, such as irritability or self-injurious behaviour, where recommended approaches have not worked.

Can a child be prescribed medical cannabis for autism in the UK?

Only in restricted circumstances, normally led by a paediatric specialist within the NHS. It is not something a private teleclinic route provides. Flora House is an adult service for people aged 18 and over.

What did the randomised trial find?

A placebo-controlled crossover trial in 150 children and adolescents reported improvement in disruptive behaviour on some measures with a whole-plant extract, but results were inconsistent across outcomes and no effect on the core features of autism was established. The authors called the findings preliminary.

What if the real problem is anxiety or sleep?

Then that is the conversation to have. A specialist will assess the specific condition rather than autism in general, and the relevant guides are those on anxiety and on sleep problems.

Sources and further reading

Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.

  1. Aran A, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism (2021)
  2. Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry (2019)
  3. NICE guideline CG170: Autism spectrum disorder in under 19s — support and management
  4. NICE guideline CG142: Autism spectrum disorder in adults — diagnosis and management
  5. NICE guideline NG144: Cannabis-based medicinal products
  6. NHS: Medical cannabis (and cannabis oils)
  7. MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use

Patient guide · Written by the Flora House editorial team · Last reviewed: 8 September 2026